SS Innovations International, Inc.
SS Innovations International designs, manufactures and markets the SSi Mantra surgical robotic system for hospitals and surgeons performing procedures across specialties including urology, general, gynecology, colorectal, gastroenterology, head and neck, thoracic and cardiac surgery. Its product range includes the SSi Mantra 3 system, SSi Mudra instruments and accessories, and digital and telesurgery products such as SSi Maya and the SSi MantraM mobile tele-surgical unit. The company also provides installation, repair, maintenance, technical support and system monitoring. SS Innovations makes money from system sales through outright purchase, deferred or installment payments, and pay-per-procedure arrangements. It also earns recurring revenue from instruments, accessories and services, selling directly to customers and through distributors. As of December 31, 2025, its installed base spans 10 countries. The company is headquartered in Gurugram, India.
No SEC Form 4 filings for $SSII in the last 30 days.
See all $SSII insider activity →Windward Bio Group (WWB) surged 40% after a $225M IPO and $50M private placement. LifeMD (LFMD) gained 30% on Q3 results and partnerships. SS Innovations (SSII) rose 20% with new leadership. Tandem Diabetes (TNDM) advanced 14% on FDA clearance for a tubeless insulin pump.
SS Innovations International, Inc. (SSII) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 SS Innovations Strengthens Management Team in Preparation for Global Sales Expansion Promotes Dr. Vishwa Srivastava to President and Appoints Gary Lo as Chief Financial Officer FORT LAUDERDALE, Fla. – November 13, 2026 – SS Innovations International, Inc. (the “Compa
SS Innovations International (SSII) reported 15,000 procedures using its SSi Mantra robotic surgical systems, including 750 cardiac and 200 telesurgeries. CEO Dr. Sudhir Srivastava highlighted the platform's 4K 3D visualization and modular design. The company plans to expand manufacturing in India and targets international growth, with first-half 2026 revenue up 66% to $25 million.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning SSII (SS Innovations International, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent SSII coverage spans financial news, corporate actions and earnings.
Management changes and regulatory update.
Executive promotions are unlikely to move the stock materially in the short term.
Positive commercial traction may lift the stock as investors price higher future sales.
The demo highlights progress in remote surgical robotics, which may improve market perception of SSII's growth prospects.
Negative earnings surprise and liquidity concerns likely pressure the stock.
AlphAI scores every news story that mentions SSII with an AI model for sentiment and relevance, and aggregates insider trades from SS Innovations International, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Windward Bio Group (WWB) surged 40% after a $225M IPO and $50M private placement. LifeMD (LFMD) gained 30% on Q3 results and partnerships. SS Innovations (SSII) rose 20% with new leadership. Tandem Diabetes (TNDM) advanced 14% on FDA clearance for a tubeless insulin pump.
SS Innovations International, Inc. (SSII) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 SS Innovations Strengthens Management Team in Preparation for Global Sales Expansion Promotes Dr. Vishwa Srivastava to President and Appoints Gary Lo as Chief Financial Officer FORT LAUDERDALE, Fla. – November 13, 2026 – SS Innovations International, Inc. (the “Compa
SS Innovations International (SSII) reported 15,000 procedures using its SSi Mantra robotic surgical systems, including 750 cardiac and 200 telesurgeries. CEO Dr. Sudhir Srivastava highlighted the platform's 4K 3D visualization and modular design. The company plans to expand manufacturing in India and targets international growth, with first-half 2026 revenue up 66% to $25 million.
SS Innovations International demonstrated its SSi Mantra robotic system and SSi MantrAsana tele-surgeon console at conferences in Spain and India, performing remote cardiac and other procedures. The company reported 205 telesurgeries as of October 23, 2026, according to an SEC filing.
SS Innovations International (SSII) shares fell 31.8% in three months, underperforming its industry and broader market. The company reported widening losses, rising operating expenses, and cash burn, with a net loss of $6.2M in H1 2026. SSII faces liquidity constraints and doubts about its ability to continue operations, despite revenue growth to $25M. It trades at a higher EV/sales multiple (8.64X) than its industry average (2.78X).
SS Innovations International, Inc. (SSII) filed an SEC Form 8-K — Other Events. Exhibit 99.1 SS Innovations Submits Response to FDA Request for Additional Information Regarding the Company’s 510(k) Submission for the SSi Mantra FORT LAUDERDALE, Fla. – October 13, 2026 – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (NASDAQ: SSII) , a
SS Innovations (NASDAQ: SSII) submitted final study data to the FDA for its SSi Mantra surgical robotic system. The company expects the FDA to complete its review by early 2027. The submission includes data from expanded clinical and bridging studies, aiming to demonstrate safety and efficacy for U.S. market approval.
SS Innovations International, Inc. (SSII) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Securities Purchase Agreement On October 9, 2026 (the “ Closing Date ” or the “ Effective Date ”), SSi entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with an institutional investor (the “ Investor ”)
SS Innovations International reported 195 robotic telesurgeries using its SSi Mantra system as of Sept 28, 2026, with 244 systems installed, up 45% from 2025. The company is expanding into 12 countries and pursuing U.S. FDA and EU CE clearances. Cumulative procedures reached 14,503.
SS Innovations (SSII) reported $42.5M revenue for 2025, up from $20.6M in 2024, with a 46.0% gross margin. The company also highlighted rapid adoption with 244 systems installed and 14,503 cumulative surgeries. Regulatory milestones include EU CE anticipated in Q4 2026 and US FDA market clearance in Q1 2027.
